Anixa Biosciences Inc - ANIX STOCK NEWS

Anixa Biosciences (NASDAQ: ANIX) has received a Notice of Allowance from the USPTO for a new patent application covering its chimeric antigen receptor-T cell (CAR-T) technology. The allowed claims encompass core methods and compositions fundamental to Anixa's innovative CAR-T approach, which is specifically designed to address challenges in applying CAR-T therapies to solid tumors.

The patent was granted to The Wistar Institute and exclusively licensed to Anixa Biosciences. The company's CAR-T technology is currently being tested in a clinical trial at Moffitt Cancer Center for treating recurrent ovarian cancer patients.

Anixa Biosciences (NASDAQ: ANIX) has received a Notice of Allowance from the USPTO for a new patent covering its breast cancer vaccine technology. The patent, exclusively licensed from Cleveland Clinic, expands the scope of immunogenic compositions in Anixa's breast cancer vaccine development.

The newly allowed patent specifically covers methods of immunizing patients against breast cancer through the administration of an immunogenic composition containing the human α-lactalbumin protein. This protein is typically expressed during lactation in breast tissue and in certain breast cancers, making it a strategic target for immunoprevention approaches.

Anixa Biosciences (NASDAQ: ANIX), a biotechnology company specializing in cancer treatment and prevention, has announced its participation in the upcoming Jones Las Vegas Healthcare and Technology Innovation Conference. The event will take place on April 8-9, 2025, at The Venetian Resort in Las Vegas.

Mike Catelani, President and CFO of Anixa, is scheduled to present on April 9, 2025, at 4:30 PM PT. The presentation will be accessible via webcast, and Catelani will be available for one-on-one meetings throughout the conference.

The two-day conference, organized by Jones with B2i Digital's marketing support, will facilitate direct interactions between company executives and institutional investors through various formats including one-on-one meetings, fireside chats, panels, presentations, and networking events.

Anixa Biosciences (NASDAQ: ANIX) has entered into a letter of intent with VERDI Solutions to develop AI-guided personalized and off-the-shelf peptide vaccines for cancer patients. VERDI's cloud-computing platform enables rapid development of personalized vaccines tailored to individual cancer patients.

The agreement grants Anixa a six-month exclusive right to negotiate the research, development, and commercialization of VERDI's cancer vaccines. VERDI has already demonstrated success in three patients with bone metastases under Europe's Individueller Heilversuch program, where patients experienced clinical benefits including significant pain relief and improved quality of life.

VERDI's proprietary algorithm predicts vaccine efficacy in recognizing and eliminating tumor cells at an individual level. While VERDI continues developing personalized vaccines in Europe, both companies plan to initiate clinical trials in the United States.

Anixa Biosciences (NASDAQ: ANIX) has received a Notice of Allowance from the USPTO for a key patent application covering its ovarian cancer vaccine technology. The patent includes broad claims related to methods of eliciting an immune response targeting Anti-Mullerian Hormone Receptor, Type II (AMHR2), which is considered a promising target for ovarian cancer prevention and treatment.

The vaccine, being developed in collaboration with Cleveland Clinic and the National Cancer Institute, represents a novel approach particularly focused on high-risk populations, including individuals with BRCA mutations or family history of ovarian cancer. The allowed claims specifically cover methods of administering an immunogenic composition comprising a nucleic acid encoding the AMHR2 polypeptide's extracellular domain to elicit an AMHR2-specific immune response.

Anixa Biosciences (NASDAQ: ANIX) announced that CEO Dr. Amit Kumar will present at the 2025 CAGLA NeauxCancer Conference on March 28th, 2025, at 10:00 AM CDT in New Orleans. The presentation, taking place at The Roosevelt Hotel, will showcase Anixa's innovative cancer treatment programs.

Dr. Kumar will provide updates on the company's cutting-edge CAR-T therapy for solid tumors and novel cancer vaccine initiatives. The presentation will highlight Anixa's progress in clinical development and their approach to advancing next-generation immunotherapies in cancer care.

The CAGLA NeauxCancer Conference, scheduled for March 27-29, 2025, brings together oncology researchers, industry executives, investors, and medical professionals to discuss breakthrough developments in cancer treatment.

Anixa Biosciences (NASDAQ: ANIX), a biotechnology company specializing in cancer treatment and prevention, has announced its 2025 Annual Meeting of Stockholders scheduled for Thursday, March 20, 2025, at 10:00 a.m. Pacific Time. The meeting will be conducted in a virtual format.

The event will feature two main segments: first, the formal business and voting portion, followed by an investor presentation and corporate update by Chairman and CEO Dr. Amit Kumar. A question-and-answer session will conclude the meeting. The company has made the meeting accessible to all interested parties through their virtual platform at www.virtualshareholdermeeting.com/ANIX2025.

Anixa Biosciences (NASDAQ: ANIX) announced that Dr. Pam Garzone, their Chief Development Officer, will participate as a panelist at the Alliance for Cancer Gene Therapy (ACGT) Summit 2025. The event will take place on March 19-20, 2025, at the Alexandria Center for Life Science in New York City.

Dr. Garzone will join the Gynecologic and Breast Cancers panel on March 19th from 11:15 AM to 12:15 PM ET. The discussion will focus on advancements in cell and gene therapy, including Anixa's CAR-T therapy for ovarian cancer and its potential impact on gynecologic and breast cancers.

Dr. Amit Kumar, Chairman and CEO of Anixa, emphasized the importance of sharing insights at the summit to advance discussions on gene-based treatments for cancer. The ACGT Summit will gather leading physician scientists working on developing curative cell and gene therapies for solid tumor cancers.

Anixa Biosciences (NASDAQ: ANIX) has completed dosing the final patient in the third cohort of its Phase 1 clinical trial for a novel CAR-T therapy targeting recurrent ovarian cancer, conducted in partnership with Moffitt Cancer Center. The third cohort received one million CAR-positive cells per kilogram, a tenfold increase from the first cohort.

The trial's fourth cohort is set to begin after a 30-day safety verification period, with plans to increase dosage by another factor of three. The therapy targets the follicle-stimulating hormone receptor (FSHR), which is exclusively expressed on ovarian cells, tumor vasculature, and certain cancer cells.

A recent protocol amendment allows eligible patients to receive a second dose if beneficial and expands enrollment criteria to include rare ovarian cancer subtypes. The first-in-human trial (NCT05316129) focuses on adult women with recurrent ovarian cancer who have progressed after at least two prior therapies, evaluating safety, maximum tolerated dose, and efficacy.